Literature DB >> 6711601

Folic acid therapy in the fragile X syndrome.

W T Brown, E C Jenkins, E Friedman, J Brooks, I L Cohen, C Duncan, A L Hill, M N Malik, V Morris, E Wolf.   

Abstract

Two brothers with fra(X) positive X-linked mental retardation (XLMR) were treated with folic acid. Initially a double blind cross-over design was employed followed by a long-term high dose trial. A decrease in the frequency of fra(X) positive cells was observed when low folic acid culture medium was used but not when an FUdR induction system was employed. Selected behavioral characteristics improved in both while receiving folic acid. Decreased hyperactivity, greater attention span, increased motor coordination, increased quantity and quality of speech were noted. Improvement in Leiter mental age and regression after cessation of treatment was seen in one subject but not in the other. Further controlled trials with larger numbers of subjects using high doses of folic acid over longer periods of time are needed to assess the possible benefits of this experimental form of treatment.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6711601     DOI: 10.1002/ajmg.1320170121

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  5 in total

1.  Folic acid blinded trial in identical twins with fragile X syndrome.

Authors:  D S Rosenblatt; E A Duschenes; F V Hellstrom; M S Golick; M J Vekemans; S F Zeesman; E Andermann
Journal:  Am J Hum Genet       Date:  1985-05       Impact factor: 11.025

Review 2.  Treatments for fragile X syndrome: a closer look at the data.

Authors:  Scott S Hall
Journal:  Dev Disabil Res Rev       Date:  2009

Review 3.  Molecular medicine of fragile X syndrome: based on known molecular mechanisms.

Authors:  Shi-Yu Luo; Ling-Qian Wu; Ran-Hui Duan
Journal:  World J Pediatr       Date:  2015-11-07       Impact factor: 2.764

4.  A combination of ascorbic acid and α-tocopherol to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebo-controlled trial.

Authors:  Yolanda de Diego-Otero; Rocio Calvo-Medina; Carolina Quintero-Navarro; Lourdes Sánchez-Salido; Francisco García-Guirado; Ignacio del Arco-Herrera; Isabel Fernández-Carvajal; Teresa Ferrando-Lucas; Rafaela Caballero-Andaluz; Lucia Pérez-Costillas
Journal:  Trials       Date:  2014-09-03       Impact factor: 2.279

Review 5.  Systematic review of pharmacological treatments in fragile X syndrome.

Authors:  Jose-Ramon Rueda; Javier Ballesteros; Maria-Isabel Tejada
Journal:  BMC Neurol       Date:  2009-10-13       Impact factor: 2.474

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.